FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Esophageal Squamous Cell Carcinoma

Therapeutic area intelligence for Esophageal Squamous Cell Carcinoma with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

oncology therapeutics →

Assets

Lactobacillus →

Phase →

Tislelizumab →

Recent signals(3)

ClinicalJuly 8, 2026

Phase II Trial of Becotatug Vedotin with Tislelizumab and Lenvatinib in Advanced ESCC

A Phase II trial is underway to evaluate the combination of Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib in patients with advanced ESCC post first-line treatment failure.

ClinicalJune 21, 2026

Lactobacillus reuteri promotes ferroptosis resistance in esophageal cancer via STAT3 lactylation

Lactobacillus reuteri induces D-lactate production, promoting STAT3 lactylation and reducing ferroptosis in ESCC.

ClinicalJune 19, 2026

Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer

A phase II trial is set to evaluate the efficacy and safety of intestinal low-dose radiotherapy combined with immunochemotherapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Esophageal Squamous Cell Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.